Efficacy and safety of the SGLT2 inhibitor empagliflozin versus placebo and the DPP-4 inhibitor linagliptin versus placebo in young people with type 2 diabetes (DINAMO): a multicentre, randomised, double-blind, parallel group, phase 3 trial.
The lancet. Diabetes & endocrinology（2023）
摘要
The Boehringer Ingelheim and Eli Lilly and Company Alliance.
更多查看译文
关键词
sglt2 inhibitor,diabetes,placebo,efficacy,double-blind
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要